MARLBOROUGH, Mass.,
Dec. 16, 2016 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) announced today that Amy Wendell has been elected to the Company's
Board of Directors, effective December 14. Ms. Wendell also
was appointed to the Company's Audit and Finance Committee.
Ms. Wendell brings to Hologic a wealth of experience in the
healthcare industry, particularly in the areas of market and
technology development. As Senior Vice President of Strategy
and Business Development for Covidien plc, until it was acquired by
Medtronic in 2015, Ms. Wendell led strategic planning and portfolio
management, as well as all business development initiatives
including mergers and acquisitions, integrations, equity
investments, divestitures, licensing, distribution and market
intelligence.
"It is a pleasure to welcome Amy to Hologic's Board of
Directors," said Steve MacMillan,
the Company's Chairman, President and Chief Executive
Officer. "Amy's strategic acumen, combined with her depth of
experience in operational, product and overall portfolio
management, are a great addition to our Board."
Ms. Wendell is also a Director of Ekso Bionics, AxoGen, Inc.,
and Por Cristo, a non-profit
organization. She received a bachelor's degree from
Lawrence Technological University
(Mich.) and a master's degree in biomedical engineering from the
University of Illinois.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal
health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions, and
statements regarding the Company's Board of Directors. These
forward-looking statements are based on assumptions made by the
Company as of this date and are subject to known and unknown risks
and uncertainties that could cause actual results to differ
materially from those anticipated. These risks include, but
are not limited to, the risk that the Company may not be able to
attract and retain qualified Board members or executives.
These risks are not exhaustive. Other factors that could
adversely affect the Company's business and prospects are described
in the filings made by the Company with the SEC. The Company
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
here to reflect any change in expectations or any change in events,
conditions or circumstances on which any such statements are
based.
Contact
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amy-wendell-elected-to-hologic-board-of-directors-300379342.html
SOURCE Hologic, Inc.